---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-061241"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2026-05-14T20:31:51+00:00"
generated_at: "2026-05-14T20:35:48.699251+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ocugen CMO Huma Qamar departs; Mohamed Genead named acting interim CMO

## Summary
- Huma Qamar separated from Ocugen as Chief Medical Officer effective May 8, 2026.
- Mohamed Genead, M.D., appointed Acting/Interim Chief Medical Officer effective May 8, 2026.
- No reason for departure or transition details were disclosed in the filing.

## SEC filing metadata
- accession: 0001104659-26-061241
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2026-05-14T20:31:51+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465926061241/0001104659-26-061241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465926061241/tm2614578d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-061241
- JSON: https://secwatch.observer/filing/0001104659-26-061241.json
- Plain text: https://secwatch.observer/filing/0001104659-26-061241.txt

## Key facts
- Executive change
  Huma Qamar departed as Chief Medical Officer at Ocugen, Inc..
  - Action: separated
  - Role: Chief Medical Officer
  source text: Effective May 8, 2026, Huma Qamar, M.D., MPH, CMI, separated from Ocugen, Inc. (the “Company”) as its Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000110465926061241/0001104659-26-061241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.